dapirolizumab pegol Updated Nov 9
The next hard catalyst is the Phase 3 PHOENYCS FLY topline readout, which Biogen guided for the first half of December 2026 on its Q3 earnings call. A positive result would strengthen the case for regulatory filings in SLE; a miss would raise doubts about the drug's profile despite PHOENYCS GO's success. Watch for the readout timing and any pre-announcement.
- The Phase 3 PHOENYCS GO study met its primary endpoint with statistical significance: 50% of patients achieved BICLA response at week 48 vs 35% on placebo (p<0.001), and results were published in The Lancet.
- Additional data presented at ACR 2026 (Nov 9, 2026) and EULAR 2026 showed benefits across multiple endpoints including fatigue reduction, flare rate reduction, and steroid-sparing effects.
- The drug targets CD40L via a novel Fc-free mechanism, which may offer a differentiated profile versus existing SLE biologics that target BLyS (Benlysta) or type 1 interferon receptor (Saphnelo).
- SLE is a notoriously difficult indication with a history of Phase 3 failures; a second confirmatory trial (PHOENYCS FLY) is still needed and could fail to replicate PHOENYCS GO's positive result.
- The SLE market already has two approved biologics (GSK's Benlysta and AstraZeneca's Saphnelo, the latter recently approved for subcutaneous self-administration), meaning dapirolizumab pegol would face established competition if approved.
- Biogen is a large-cap company with a diversified portfolio; dapirolizumab pegol is only one of several pipeline assets, so even a positive readout may have limited impact on BIIB shares.